A product launch isn't merely a release date; it's a strategic, coordinated campaign. Its primary goal is to change the market's perception, generate demand, and create momentum across the entire funnel, moving beyond a simple product announcement.

Despite sound science, many recent drug launches are failing. The root cause is not the data but an underinvestment in market conditioning. Cautious investors and tighter budgets mean companies are starting their educational and scientific storytelling efforts too late, failing to prepare the market adequately.

If everyone in the company instantly understands and agrees with your launch message, it might be too safe. A great launch reframes the market, which should provoke some initial internal skepticism. This indicates the message is bold enough to break through external noise.

To save a struggling product launch, you cannot wait for quarterly reviews. Implement a rapid, monthly feedback loop to assess messaging perception and performance. This allows the entire cross-functional team to adjust the strategy and execution plan in real-time before negative market perception solidifies.

Many founders mistakenly believe achieving product-market fit is the final step to explosive growth. However, growth only ignites after also finding a repeatable go-to-market fit, which translates the founder's initial sales success into a scalable process that a sales team can execute consistently.

Early-stage MedTech companies often have a limited, narrow understanding of their market size and product-market fit. Their intense focus on product development and regulatory hurdles causes them to neglect crucial commercialization planning, creating a major strategy gap post-approval.

Many MedTech companies mistakenly believe a clinically superior product will automatically win market share. This is false. Market adoption is not automatic; it must be designed as intentionally as the product itself to overcome the powerful inertia of the status quo and make the market mentally ready for change.

When sales stall, founders assume the market isn't interested. More often, it's an execution problem: they fail to listen to clear demand signals or pitch irrelevant features, creating a self-inflicted "demand problem."

A primary driver of recent pharma launch failures is underinvestment in pre-launch market conditioning. Cautious investors and tighter budgets mean companies have fewer resources to tell their scientific story effectively before launch. This delayed and underfunded approach has a dramatic negative impact on commercial success.